Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to ensure that the lowest approved dose of Aranesp is used to maintain haemoglobin at a level that controls the symptoms of anaemia.
Kui individuaalse patsiendi ravieesmärk on saavutatud, peab annust vähendama 25% … 50% võrra, säilitamaks hemoglobiini tasemel, mis tagab aneemia adekvaatse sümtomaatilise ravi madalaima kinnitatud Aranesp’ i annusega.